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BaCKgRoUND aND aIMS: Data regarding outcome of 
COVID- 19 in patients with autoimmune hepatitis (AIH) are 
lacking.
appRoaCH aND ReSUltS: We performed a retrospective 
study on patients with AIH and COVID- 19 from 34 cent-
ers in Europe and the Americas. We analyzed factors associ-
ated with severe COVID- 19 outcomes, defined as the need 
for mechanical ventilation, intensive care admission, and/or 
death. The outcomes of patients with AIH were compared 
to a propensity score– matched cohort of patients without 
AIH but with chronic liver diseases (CLD) and COVID- 19. 
The frequency and clinical significance of new- onset liver in-
jury (alanine aminotransferase  >  2 × the upper limit of nor-
mal) during COVID- 19 was also evaluated. We included 110 
patients with AIH (80% female) with a median age of 49 
(range, 18- 85) years at COVID- 19 diagnosis. New- onset liver 
injury was observed in 37.1% (33/89) of the patients. Use of 
antivirals was associated with liver injury (P  =  0.041; OR, 
3.36; 95% CI, 1.05- 10.78), while continued immunosuppres-
sion during COVID- 19 was associated with a lower rate of 
liver injury (P  =  0.009; OR, 0.26; 95% CI, 0.09- 0.71). The 
rates of severe COVID- 19 (15.5% versus 20.2%, P  =  0.231) 
and all- cause mortality (10% versus 11.5%, P  =  0.852) were 
not different between AIH and non- AIH CLD. Cirrhosis 
was an independent predictor of severe COVID- 19 in pa-
tients with AIH (P  <  0.001; OR, 17.46; 95% CI, 4.22- 72.13). 
Continuation of immunosuppression or presence of liver injury 
during COVID- 19 was not associated with severe COVID- 19.
CoNClUSIoNS: This international, multicenter study re-
veals that patients with AIH were not at risk for worse out-
comes with COVID- 19 than other causes of CLD. Cirrhosis 
was the strongest predictor for severe COVID- 19 in pa-
tients with AIH. Maintenance of immunosuppression during 
COVID- 19 was not associated with increased risk for severe 
COVID- 19 but did lower the risk for new- onset liver injury 
during COVID- 19. (Hepatology 2021;73:2099-2109).
COVID- 19, caused by the severe acute respiratory syndrome coronavirus 2, was first described in December 2019 in Wuhan, China.(1) Following 
this first report, it rapidly spread worldwide and caused 
an international pandemic. Most COVID- 19 cases 
have mild symptoms, but the disease can result in 
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hospitalization, progression to respiratory failure, and 
death.(2- 4) Older age, cardiovascular diseases, chronic 
lung diseases, active cancer, obesity, and diabetes mel-
litus are risk factors for severe COVID- 19 outcomes.(5) 
COVID- 19 often affects the liver, and individuals with 
underlying chronic liver diseases (CLD) have high rates 
of hospitalization and mortality.(6,7)
Autoimmune hepatitis (AIH) is a chronic immune- 
mediated liver disease.(8) Corticosteroids alone or in 
combination with azathioprine is the standard ther-
apy in AIH. Several alternative immunosuppressive 
drugs, including tacrolimus, mycophenolate mofetil 
(MMF), methotrexate, 6- mercaptopurine (6- MP), 
rituximab, and infliximab, are used in patients who do 
not respond or are intolerant to standard therapy.(8,9) 
The majority of patients with AIH require lifelong 
immunosuppressive therapy, which may increase the 
risk of bacterial and viral infections.(8) Existing data 
regarding the clinical presentation and outcome of 
COVID- 19 in patients with AIH are limited to small 
case series and expert opinions.(10,11) The stage of liver 
disease has been shown to be a risk factor, but it is 
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unclear whether the type of underlying liver disease 
is a major contributing factor to poor outcomes with 
COVID- 19. Specifically for AIH, immunosuppressive 
therapy enhances the risk of severe COVID- 19. On 
the other hand, it may be argued that immunosup-
pression protects against the inappropriate immune 
response, or cytokine storm, which is a characteristic 
of severe COVID- 19.(12)
The aims of this international multicenter study 
were to assess the clinical characteristics and outcomes 
of patients with AIH infected with COVID- 19 and 
to explore the frequency and factors associated with 
new- onset liver injury and severe COVID- 19 out-
come in these patients.
Materials and Methods
StUDy DeSIgN
We retrospectively evaluated data of patients with 
AIH who were diagnosed with COVID- 19 between 
March 11 and November 12, 2020, from 34 cen-
ters in 10 countries. All participants independently 
identified patients and collected data from elec-
tronic health records and patients’ follow- up charts. 
Patients with AIH who were older than 16 years at 
the time of COVID- 19 with a diagnosis confirmed 
by a PCR- based test were included in the study. 
Patients with typical radiological findings but with 
negative PCR tests were not included. All patients 
with AIH, or overlap with primary biliary cholan-
gitis (PBC) or primary sclerosing cholangitis (PSC), 
were diagnosed and treated according to interna-
tional guidelines.(8,13)
The presence of cirrhosis was diagnosed based on 
standard imaging studies (elastography, ultrasound, 
CT, or MRI), liver tissue examination, or clinical 
findings of portal hypertension or its complications. 
Complete biochemical response was defined as nor-
mal alanine aminotransferase (ALT), aspartate ami-
notransferase (AST) and immunoglobulin G (IgG) 
levels. Partial response was defined as a decrease of 
ALT or AST to below 2 times the upper limit of 
normal (ULN), and nonresponse was defined as 
persistently elevated transaminase levels more than 
2 times the ULN despite appropriate immunosup-
pressive therapy.(8,13) High alcohol consumption was 
defined as more than 2 drinks/day for men and more 
than 1 drink/day for women.(14)
New- onset liver injury was defined as rising ALT 
values during COVID- 19 and categorized as no 
or mild (< 2 × ULN), moderate (2- 5 × ULN), or 
severe (>5 × ULN). New- onset ALT > 2 × ULN was 
used as the definition of liver injury for the study. 
Patients who were nonresponders to AIH therapy 
were excluded from new- onset liver injury analysis as 
they already had ALT  >  2 × ULN levels before the 
COVID- 19 diagnosis. The cutoffs for normal values 
of ALT were considered 25 U/L for women and 35 
U/L for men.(15) Severe COVID- 19 infection was 
defined as a composite of intensive care unit (ICU) 
admission, ventilator use, and/or death, in line with 
previously reported COVID- 19 data.(3) The Harran 
University Hospital of Şanlıurfa was the coordinating 
center (HRE ID 2020- 00682), and the local ethical 
review boards of the participating centers approved 
the study.
Data ColleCtIoN
Collected patient data included general informa-
tion on patients, autoimmune liver serology, types 
and doses of immunosuppression, the patient’s AIH 
response status at last follow- up before COVID- 19, 
and presence of cirrhosis. At the time of COVID- 19 
diagnosis, body mass index (BMI), clinical features, 
and comorbid conditions were recorded. Laboratory 
values at COVID- 19 diagnosis and at peak/worst val-
ues any time in the first month of COVID- 19 were 
used to evaluate liver injury. Any modification in the 
dose or type of immunosuppressive drugs during 
COVID- 19, highest care level, hospitalization time, 
specific COVID- 19 therapies, and patient outcomes, 
providing a minimum of 4 weeks after COVID- 19, 
were recorded.
In order to determine how AIH impacts clini-
cal outcomes with COVID- 19, we compared AIH 
patients to a control group of patients with non- 
AIH CLD and COVID- 19. To identify a control 
group, we used data from a multicenter, observa-
tional study of adult patients with CLD and PCR- 
confirmed COVID- 19. More details regarding the 
inclusion and exclusion criteria of this cohort have 
been published.(7) Only patients without AIH from 
this cohort were included in the control group. 
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None of the patients in the control group were on 
immunosuppression.
StatIStICal aNalySIS
Continuous variables are presented as mean with 
standard deviation or as median with range. The 
Student t test or the Mann- Whitney U test was used 
for comparisons, as appropriate depending on the dis-
tribution. Categorical variables are presented as num-
bers and percentages, and the chi- squared test was used 
for comparisons. Multivariable logistic regression anal-
ysis models were performed to predict the two major 
outcomes of the study (dependent variables): signif-
icant new- onset liver injury and severe COVID- 19. 
According to the predefined statistical plan, we eval-
uated associations between each independent variable 
and outcome after having analyzed the number of out-
come events. In addition to predefined sex and age in 
terms of their clinical relevance for the outcomes, inde-
pendent variables with a statistically significant rela-
tionship (P < 0.1) with dependent (outcome) variables 
in the univariate analysis were then included in the 
multivariable models. Hosmer- Lemeshow goodness- 
of- fit statistics were used to assess model fit. P < 0.05 
was considered to represent statistical significance.
We compared clinical outcomes of COVID- 19 in 
patients with AIH and non- AIH CLD. We used pro-
pensity score analysis to identify a cohort of patients with 
non- AIH CLD and COVID- 19 who were statistically 
matched on a 1:2 basis using the nearest neighbor 
approach. We matched AIH and non- AIH for crucial 
variables which are known to impact clinical outcomes 
with COVID- 19 including age, gender, presence of cir-
rhosis, diabetes mellitus, hypertension, and heart diseases.
Results
geNeRal CHaRaCteRIStICS oF 
tHe StUDy popUlatIoN
Medical data of 115 patients with AIH who acquired 
COVID- 19 were analyzed. Five patients were excluded: 
3 patients had previously undergone liver transplanta-
tion, and 2 patients were concomitantly diagnosed with 
AIH and COVID- 19 (Fig.  1). The final study group 
included 110 patients with AIH (80% female) with a 
median age of 49 (range, 18– 85) years at COVID- 19 
infection. Four of these patients had been included in 
a previous study.(11) The general characteristics, clini-
cal features, and outcomes of the patients are presented 
in Table  1. Twelve (10.9%) patients had overlap with 
PBC and 4 (3.6%), with PSC. Coexistence of other 
immune- mediated disorders was noted in 28 (25.5%) 
patients, including autoimmune thyroid diseases in 
17 (15.4%) patients, inflammatory bowel diseases in 3 
(2.7%), Sjögren syndrome in 2 (1.8%), systemic sclero-
sis in 2 (1.8%), rheumatoid arthritis in 2 (1.8%), sys-
temic lupus erythematosus in 1 (0.9%), celiac disease in 
FIg. 1. Study flowchart for patient inclusion.
AIH patients with COVID-19
(n=115)
Excluded (n=5)
Liver transplant before COVID-19
Concomitant AIH and COVID-19 diagnosis




Alive (n=59) Alive (n=40)
Hospitalized (n=51)
Died (n=11)
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1 (0.9%), ankylosing spondylitis in 1 (0.9%), and anti-
phospholipid syndrome in 1 (0.9%).
aIH CHaRaCteRIStICS BeFoRe 
CoVID- 19
At last follow- up before COVID- 19 diagno-
sis, 88 (80%) patients were complete responders, 
taBle 1. Demographics, Clinical Features, and outcomes of 
Study population (n = 110)
Region
North America, n (%) 34 (30.9)
South America, n (%) 22 (20)
Europe, n (%) 54 (49.1)
Sex (female), n (%) 88 (80)
Overlap syndromes (PBC/PSC), n (%) 12/4 (10.9)/(3.6)
Concomitant autoimmune diseases, n (%) 28 (25.5)
ANA, n (%)* 77 (76.5)
SMA, n (%)† 46 (45.1)
LKM- 1, n (%)‡ 3 (3.8)
LC- 1, n (%)§ 3 (6.2)
SLA, n (%)|| 2 (4.1)
AIH activity at last visit before COVID- 19
Complete response, n (%) 88 (80)
Partial response, n (%) 19 (17.3)
Nonresponse, n (%) 3 (2.7)
Presence of cirrhosis, n (%) 32 (29.1)
Features of patients with AIH at COVID- 19 infection
Age (years), mean (SD) 47.9 (15.8)
Time from AIH diagnosis, median (months) 60 (1- 480)
BMI, kg/m2, mean (SD) 26.5 (5.3)





Coronary artery disease 5 (4.5)
Atrial fibrillation 2 (1.8)
Heart failure 2 (1.8)
Respiratory disease 9 (8.3)
Cancer history 5 (4.5)
Kidney insufficiency 1 (0.9)
Immunosuppressive therapy before COVID, n (%) 102 (92.7)
Azathioprine/6- MP 27 (24.5)
Azathioprine/6- MP + prednisolone/budesonide 39 (35.4)














Prednisolone/budesonide + tacrolimus +MMF 1 (0.9)
MMF 3 (2.7)
Sirolimus 1 (0.9)






Fatigue and/or myalgia 65 (59.1)
Anosmia 19 (17.3)
Gastrointestinal symptoms, n (%) 30 (27.2)




Continued immunosuppression during COVID- 19, 
n (%)
69 (62.7)
Antibiotic therapy during COVID- 19, n (%) 40 (36.4)






High- dose steroids 15 (13.6)
Rituximab 1 (0.9)
Tocilizumab 1 (0.9)
Low– molecular weight heparin 26 (23.6)
Plasma exchange 3 (2.7)
Oxygen therapy, n (%) 42 (38.2)
Nasal cannula 25 (22.7)
Noninvasive ventilation/mechanical ventilation 9 (8.2)/8 (7.3)
New- onset liver injury during COVID- 19, n (%)¶ 33 (37.1)
Outcome of study population
Hospitalized, n (%) 51 (46.4)
Intensive care admission, n (%) 15 (13.6)
Death, n (%) 11 (10)
*ANA was available in 101 patients; BMI was available in 83.
†SMA was available in 101 patients.
‡LKM- 1 was available in 80 patients.
§LC1- 1 was available in 48 patients.
||SLA was available in 48 patients.
¶Liver injury was evaluated in 89 patients.
Abbreviations: ANA, antinuclear antibody; LC- 1, liver- cytosol 
type 1; LKM- 1, liver kidney microsome type 1; SLA, soluble liver 
antigen; SMA, smooth muscle antibody.
taBle 1. Continued
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19 (17.3%) were partial responders, and 3 (2.7%) 
were nonresponders. Thirty- two (29.1%) patients 
with AIH had features of cirrhosis. A total of 53 
(48.2%) patients had comorbid conditions; diabetes 
mellitus (n = 27, 24.5%) and hypertension (n = 26, 
23.6%) were the most common. Seven (6.4%) 
patients reported active smoking, and 2 (1.8%) had 
high alcohol consumption. Five (4.5%) patients had 
a history of malignancy, two cases of which were 
active during COVID- 19.
Most patients (92.7%) were on immunosup-
pressive therapy prior to the COVID- 19 diagnosis. 
Eight patients (7.3%) were not on immunosuppres-
sive therapy; 6 patients had withdrawn therapy (3 
by themselves and 3 by a physician), 1 patient was 
a nonresponder to available therapies, and 1 had 
inactive (“burned- out”) cirrhosis. At the time of 
COVID- 19 diagnosis, 65 (59.1%) patients were on 
prednisone therapy (alone or in combination with 
other immunosuppressants) with a median dose of 
5 (range, 2.5- 60) mg/day. Among them, 25 (22.7%) 
patients were on prednisone ≥ 10  mg/day. The 
patients’ immunosuppressive therapies are presented 
in Table 1.
MaNageMeNt oF aIH DURINg 
CoVID- 19
The majority of patients (n = 96, 87.3%) were symp-
tomatic at the time of COVID- 19 diagnosis; cough 
(n  =  68, 61.8%) and fever (n  =  65, 59.1%) were the 
most commonly reported symptoms. Gastrointestinal 
symptoms (abdominal pain, diarrhea, nausea, and 
vomiting) were noted in 30 (27.2%) patients.
The dose or type of immunosuppression was modified 
in 33 (30%) patients during COVID- 19 but remained 
unchanged in 69 (62.7%). General characteristics of the 
patients according to immunosuppressive therapy status 
are presented in Table  2. Among patients on azathio-
prine/6- MP monotherapy (n = 10), doses were reduced 
in 3 and discontinued in 7. Among patients on steroid 
monotherapy (n = 2), the dose was reduced in 1 and dis-
continued in 1. In patients treated with a combination 
of azathioprine/6- MP and steroids (n = 14), the dose of 
only azathioprine/6- MP was reduced in 1 and discon-
tinued in 5, the dose of only steroids was reduced in 5, 
while the doses of both azathioprine/6- MP and steroids 
were reduced in 1 and discontinued in 2. Azathioprine 
was discontinued and tacrolimus reduced in a patient 
who was treated with both drugs. In 1 patient who was 
on triple immunosuppression, azathioprine was discon-
tinued, and both the steroid and tacrolimus doses were 
reduced. Among patients treated with MMF and ste-
roids (n  =  4), only MMF was discontinued in 3, and 
both drugs were reduced in 1. The dose was reduced in 
a patient on MMF monotherapy.
Antibiotics were given to 40 (36.4%) patients 
during COVID- 19 infection. Sixty- seven (60.9%) 
patients received specific therapy for COVID- 19. 
Hydroxychloroquine (n  =  29, 26.4%) and antivirals 
(n  =  22, 20%) were the most commonly used ther-
apies. High- dose steroids were given to 15 (13.6%) 
patients, and plasma exchange was performed in 3 
(2.7%) patients. Tocilizumab and rituximab were used 





Age > 65 (years) 13 (18.8) 4 (9.8) 0.278
Gender (female) 57 (82.6) 31 (75.6) 0.461
BMI > 30 8 (16.3) 8 (23.5) 0.572
Comorbidity 37 (53.6) 18 (43.9) 0.430
Cirrhosis 21 (30.4) 11 (26.8) 0.829
Remission before COVID- 19 60 (87) 28 (68.3) 0.026
Symptoms at presentation 59 (85.5) 37 (90.2) 0.564
Treatment for COVID- 19 43 (62.3) 24 (58.5) 0.840
New- onset liver injury* 12 (22.6) 21 (58.3) 0.001
Severe COVID- 19 10 (14.5) 7 (17.1) 0.788
All- cause mortality 4 (5.8) 7 (17.7) 0.096
*New- onset liver injury was evaluated in 89 patients.
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in 1 (0.9%) patient each. The details of COVID- 19 
therapies are presented in Table 1.
lIVeR INJURy DURINg CoVID- 19
New- onset liver injury was reported in 37.1% 
(33/89) of the patients: 16 (18%) had moderate and 17 
(19.1%) had severe liver injury. New- onset liver injury 
was observed in 85.7% (6/7) of patients who were not 
on immunosuppression, in 51.7% (15/29) of patients 
whose immunosuppression was modified, and in 22.6% 
(12/53) of patients whose immunosuppression was 
unchanged during COVID- 19. Predictors of liver injury 
are presented in Table 3. Multivariate regression analysis 
revealed that antivirals (defined in Table 1) were associ-
ated with new- onset liver injury (P = 0.041; OR, 3.36; 
95% CI, 1.05- 10.78) and that continued immunosup-
pression during COVID- 19 reduced the probability of 
liver injury (P = 0.009; OR, 0.26; 05% CI, 0.09- 0.71).
oUtCoMeS oF CoVID- 19 IN 
patIeNtS WItH aIH CoMpaReD 
to NoN- aIH ClD
When the outcomes of patients with AIH 
(n  =  110) were compared to a cohort of non- AIH 
patients with CLD (n  =  220) and COVID- 19 
(Supporting Table  S1), no statistically significant 
differences were noted regarding the rates of all- 
cause mortality (10% versus 11.5%; P  =  0.852), 
severe COVID- 19 (15.5% versus 20.2%; P = 0.231), 
need for supplemental oxygen (38.2% versus 42.2%; 
P = 0.553), and hospitalization (46.4% versus 50.0%; 
P = 0.560) (Fig. 2).
Seventeen AIH patients had severe COVID- 19, 
and 11 patients died due to COVID- 19. Predictors of 
severe outcomes in patients with AIH are presented 
in Table 4. After adjusting for age, gender, coexistence 
of PBC/PSC or extrahepatic autoimmune diseases, 
and AIH therapy response, the presence of cirrhosis 
was independently associated with severe COVID- 19 
(P < 0.001; OR, 17.46; 95% CI, 4.22- 72.13). Patients 
with AIH and comorbid conditions (defined in 
Table 1) tended to have severe COVID- 19 infection 
(P  =  0.06; OR, 4.16; 95% CI, 0.94- 18.36). Presence 
of liver injury and continued immunosuppression 
during COVID- 19 were not associated with severe 
COVID- 19.
Discussion
In this international multicenter study, we eval-
uated the clinical presentation, laboratory features, 
and outcomes of COVID- 19 in patients with AIH. 
In our study population, 37.1% of the patients devel-
oped new- onset liver injury during COVID- 19. 
Among 110 patients with AIH, 15.5% had severe 
COVID- 19, and 10% died. Our data show that (1) 
the overall outcome of COVID- 19 was favorable in 
taBle 3. Univariate and Multivariate analyses of New- onset liver Injury in patients With aIH and CoVID- 19
Univariate Analysis Multivariate Analysis
OR 95% CI P OR 95% CI P
Sex (female) 1.21 0.37- 3.93 0.742 1.85 0.42- 8.05 0.407
Age (>65 years) 0.56 0.16- 1.94 0.364 0.76 0.18- 3.10 0.704
BMI (>30) 2.05 0.62- 6.75 0.235
Complete response to therapy 0.27 0.09- 0.85 0.025 0.27 0.06- 1.15 0.077
Cirrhosis 1.05 0.42- 2.63 0.908
Comorbidities 1.06 0.44- 2.51 0.890
Immunosuppression 
maintenance
0.20 0.08- 0.52 0.001 0.26 0.09- 0.71 0.009
Antibiotics 1.64 0.68- 3.91 0.263
Antivirals 3.00 1.06- 8.49 0.039 3.36 1.05- 10.78 0.041
Hydroxychloroquine 0.86 0.33- 2.23 0.757
High- dose steroid 0.82 0.25- 2.65 0.742
O2 therapy (any) 2.56 1.06- 6.20 0.037 2.23 0.81- 6.13 0.118
Comorbidities and antivirals are presented in Table 1.
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patients without cirrhosis, (2) ongoing immunosup-
pression was not associated with increased risk of 
severe COVID- 19, and (3) maintenance of immuno-
suppression was associated with a lower risk for new- 
onset liver injury.
We found similar rates of severe COVID- 19 
outcome and mortality in patients with AIH and 
a matched control group of non- AIH CLD and 
COVID- 19. Among patients with AIH, those with 
cirrhosis had higher risk for severe COVID- 19 out-
comes (43.8% versus 3.9%). Overall mortality was 
also significantly higher in patients with cirrhosis 
than those without (31.3% versus 1.3%). In line with 
our results, other studies have reported 30%- 34% 
mortality rates in patients with cirrhosis.(16,17) These 
results suggest that, regardless of etiology, cirrhosis 
is a strong predictor of worse prognosis in patients 
with COVID- 19. Consistent with previous reports,(5) 
patients with AIH and comorbid conditions in our 
study tended to have severe COVID- 19.
New- onset liver injury was observed in 37.1% 
during COVID- 19. Other studies have reported the 
rate to be 27.4% in a general population,(18) 34.6% in 
liver transplant recipients, and 47.5% in patients with 
CLD.(19) Liver injury was found to be a predictor of 
poor outcome in these studies.(7,18,19) In our AIH 
cohort, liver injury was not associated with adverse 
COVID- 19 outcomes. There are several possible 
causes of liver injury in COVID- 19, and all causes 
probably do not carry the same mortality risk.(18,20) 
Patients who develop hepatocyte necrosis induced by 
systemic inflammatory response syndrome or isch-
emic injury due to circulatory or respiratory failure 
may have a higher mortality risk compared to those 
who have a drug- induced liver injury or develop 
an AIH relapse. The similar outcomes of patients 
with and without liver injury in our study might be 
explained by the likely incidence of AIH relapse or 
drug- induced liver injury, both manageable causes of 
liver injury.
Relapse of AIH following infection is a well- known 
phenomenon.(14) COVID- 19 can trigger hyperstim-
ulation of the immune system, an event associated 
with high serum levels of inflammatory cytokines 
and chemokines.(12) Four patients with AIH and 
FIg. 2. Clinical outcomes of COVID- 19 in patients with AIH 
compared to non- AIH CLD. All- cause mortality (10% versus 
11.5%), severe COVID- 19 (15.5% versus 20.2%), need for 
supplemental oxygen (38.2% versus 42.2%), and hospitalization 
(46.4% versus 50%). P  =  nonsignificant for all comparisions. 
Abbreviation: ns, nonsignificant.
taBle 4. Univariate and Multivariate analyses for predictors of Severe CoVID- 19 in patients With aIH
Univariate Analysis Multivariate Analysis
OR 95% CI P OR 95% CI P
Sex (female) 1.19 0.31- 4.59 0.792 2.20 0.44- 10.82 0.330
Age (>65 years) 2.81 0.84- 9.40 0.093 1.03 0.23- 4.48 0.964
Overlap of PBC/PSC 1.31 0.33- 5.23 0.694
Extrahepatic autoimmune 
diseases
1.26 0.40- 3.98 0.684
BMI (>30) 1.94 0.44- 8.54 0.378
Comorbidities 6.46 1.73- 24.02 0.005 4.16 0.94- 18.36 0.060
Prednisolone (≥10 mg) 2.12 0.70- 6.48 0.192
Complete response to therapy 0.53 0.16- 1.72 0.297
Cirrhosis 19.44 5.04- 74.92 <0.001 17.46 4.22- 72.13 <0.001
Immunosuppression 
maintenance
0.82 0.28- 2.36 0.718
Acute liver injury 1.67 0.57- 4.86 0.346
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nonsevere COVID- 19 had new- onset liver injury 
along with high IgG levels, thus suggesting that they 
experienced AIH relapse rather than COVID- 19- 
induced liver injury (Table  5). Development of vari-
ous inflammatory or autoimmune conditions has been 
reported during or shortly after COVID- 19.(12,21) 
Some case reports have suggested that AIH presents 
for the first time during COVID- 19.(21,22) In fact, 2 
patients in our cohort (both excluded) did receive their 
initial diagnosis of AIH during COVID- 19. Overall, 
our results suggest that COVID- 19 may be associated 
with new onset or flare of AIH, especially in patients 
whose immunosuppression is reduced.
A lack of clear data has made it difficult to make 
definitive recommendations for management of 
immunosuppression during COVID- 19. In our study, 
the doses and types of immunosuppression were con-
tinued unchanged in 62.7% of the patients when they 
acquired COVID- 19, and this was not associated with 
adverse COVID- 19 outcomes. Two previous stud-
ies(19,23) also reported that continued immunosuppres-
sion did not increase the risk of severe COVID- 19 
in liver transplant recipients; only MMF usage was 
linked to severe COVID- 19 outcome.(23) In our study, 
MMF was discontinued or reduced in 62.5% (5/8) of 
the patients who were on this drug. Also, therapy with 
prednisone (≥ 10 mg/day) was associated with higher 
hospitalization rates in a rheumatology setting,(24) 
and similar results were also reported in patients with 
inflammatory bowel disease.(25) However, the rates 
of severe COVID- 19 were not different in patients 
with AIH who were on prednisone ≥10 mg/day com-
pared to patients on <10  mg/day (24 versus 12.9%, 
P  =  0.211). Due to the low number of patients who 
were on ≥10 mg/day prednisone or MMF therapy, we 
cannot draw definitive conclusions about the associ-
ated risks. Of note, patients whose immunosuppressive 
therapy was modified during COVID- 19 experienced 
higher rates of liver injury or AIH relapse than those 
in whom immunosuppressive therapy was not modi-
fied. Relapse of AIH due to reduction or withdrawal 
of immunosuppression during COVID- 19 represents 
diagnostic and therapeutic challenges. Elevated ami-
notransferases may be misinterpreted as a marker for 
severe COVID- 19 and lead to unnecessary hospital-
izations. Induction therapy to achieve AIH remission 
requires higher doses of immunosuppression, which 
may adversely affect the outcome of COVID- 19. Our 
results support maintaining immunosuppressive ther-
apy during COVID- 19.
We acknowledge that the retrospective nature of our 
study is a main limitation. However, given the unprec-
edented nature of the pandemic and the low prevalence 
of AIH, we believe that our study offers valuable insights 
into the management of these patients. Another limita-
tion is the possibility of selection bias because asymp-
tomatic patients and those with mild disease were likely 
not included in our study. We have, however, included 
both outpatients and inpatients, and > 50% our study 
population were outpatients. We also observed that 
some of the hospitalized patients had a short hospi-
tal stay. Because patients with AIH were immunosup-
pressed or had concomitant comorbid conditions and 
because of a lack of information about appropriate use 
of immunosuppressive therapy during COVID- 19, it 
is possible that patients were admitted out of caution 
and that hospitalization may not necessarily reflect 
the severity of COVID- 19. We also found that man-
agement and therapeutic strategies for COVID- 19 
vary significantly between centers and countries. To 
taBle 5. Characteristics of patients With aIH and Features of Disease Relapse During CoVID- 19









1 F 60 AIH Complete Azathioprine, 50 mg/day, 
Prednisolone, 5 mg/day
Home 6.9/1.1 Azathioprine and predniso-
lone increased/Yes





6.8/1.7 MMF switched to 
tacrolimus/Yes
3 F 44 AIH Complete In remission without 
therapy
Home 4.3/1.2 Azathioprine and predniso-
lone added/Yes





Abbreviation: UDCA, ursodeoxycholic acid.
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overcome these limitations, we used widely accepted 
clinical endpoints of severe COVID- 19 infection like 
ICU admission, need for mechanical ventilation, and/
or death.(3,23,25)
Our study also has several strengths. We derived 
data from many hepatology centers across Europe and 
the Americas, and this represents the largest cohort 
describing COVID- 19 in AIH to date. Moreover, we 
collected detailed information on immunosuppression 
changes during the course of COVID- 19, allowing us 
to discern the effects of dose reductions and modifi-
cations on clinical outcomes. Lastly, we compared the 
AIH cohort with a matched non- AIH cohort, which 
allowed us to examine the impact of AIH itself on 
clinical outcomes of COVID- 19.
In conclusion, this large multicenter study of 
patients with AIH and COVID- 19 found overall 
mortality and severe COVID- 19 rates of 10% and 
15.5%, respectively. Patients with AIH, despite being 
immunosuppressed, did not experience worse clinical 
outcomes with COVID- 19 than patients with non- 
AIH CLD. Presence of cirrhosis was the strongest pre-
dictor of severe COVID- 19, and the overall outcome 
of COVID- 19 was favorable in patients with noncir-
rhotic AIH. Maintenance of immunosuppression was 
associated with lower risk of new- onset liver injury. We 
recommend that immunosuppression not be decreased 
or discontinued upon diagnosis of COVID- 19.
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